• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经皮肾肿瘤冷冻消融或微波消融患者经皮肾消融复杂性评分系统的外部验证。

External Validation of the Percutaneous Renal Ablation Complexity Scoring System in Patients Undergoing Percutaneous Cryoablation or Microwave Ablation of Renal Tumors.

机构信息

Division of Vascular and Interventional Radiology, University of Alabama at Birmingham, Birmingham, Alabama.

Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.

出版信息

J Vasc Interv Radiol. 2022 Dec;33(12):1588-1593. doi: 10.1016/j.jvir.2022.08.021. Epub 2022 Aug 20.

DOI:10.1016/j.jvir.2022.08.021
PMID:35998804
Abstract

PURPOSE

To assess the ability of the Percutaneous Renal Ablation Complexity (P-RAC) scoring system to predict procedural complexity or adverse events (AEs) in adult patients undergoing percutaneous thermal ablation of renal tumors.

MATERIALS AND METHODS

A retrospective review of 240 consecutive adult patients who underwent percutaneous thermal renal ablation from 2004 to 2018 was conducted. The P-RAC score was calculated for each renal tumor and procedural complexity recorded. A correlation coefficient was calculated for the P-RAC score and both the number of probes used and procedural duration. Receiver operating characteristic curves assessed the score's ability to predict the use of adjunctive techniques and/or major AEs, classified according to the Society of Interventional Radiology guidelines.

RESULTS

For the entire cohort, there was a weak correlation between P-RAC scores and both the number of probes used (r = 0.31; P < .001) and procedural duration (r = 0.18; P = .03). When evaluating only patients treated with microwave ablation (MWA), no correlation between P-RAC scores and either the number of probes (P = .7) used or procedural duration (P = .4) was found. The area under the curve (AUC) for the P-RAC score to predict the use of adjunctive techniques was 0.55 and 0.53 for the entire cohort and MWA group, respectively. The AUC for the P-RAC score to predict major AEs was 0.70, 0.71, and 0.73 for the entire cohort, MWA group, and cryoablation group, respectively.

CONCLUSIONS

The P-RAC scoring system is limited in its ability to predict percutaneous thermal renal tumor ablation procedural complexity, especially in patients treated with MWA. The scoring system may have a role in identifying patients at risk of major AEs.

摘要

目的

评估经皮肾消融复杂度(Percutaneous Renal Ablation Complexity,P-RAC)评分系统预测成人接受经皮热消融肾肿瘤治疗的手术复杂度或不良事件(Adverse Events,AEs)的能力。

材料与方法

对 2004 年至 2018 年间 240 例连续接受经皮热肾消融治疗的成年患者进行回顾性研究。为每个肾肿瘤计算 P-RAC 评分,并记录手术复杂度。计算 P-RAC 评分与使用的探针数量和手术持续时间之间的相关系数。根据介入放射学会指南,使用受试者工作特征曲线评估评分预测辅助技术和/或主要 AEs 的能力。

结果

在整个队列中,P-RAC 评分与使用的探针数量(r=0.31;P<0.001)和手术持续时间(r=0.18;P=0.03)之间存在弱相关性。仅评估接受微波消融(Microwave Ablation,MWA)治疗的患者时,发现 P-RAC 评分与使用的探针数量(P=0.7)或手术持续时间(P=0.4)之间无相关性。P-RAC 评分预测辅助技术使用的曲线下面积(Area Under the Curve,AUC)在整个队列和 MWA 组中分别为 0.55 和 0.53。P-RAC 评分预测主要 AEs 的 AUC 在整个队列、MWA 组和冷冻消融组中分别为 0.70、0.71 和 0.73。

结论

P-RAC 评分系统在预测经皮热肾肿瘤消融手术复杂度方面能力有限,尤其是在接受 MWA 治疗的患者中。该评分系统可能有助于识别发生重大 AEs 的风险患者。

相似文献

1
External Validation of the Percutaneous Renal Ablation Complexity Scoring System in Patients Undergoing Percutaneous Cryoablation or Microwave Ablation of Renal Tumors.经皮肾肿瘤冷冻消融或微波消融患者经皮肾消融复杂性评分系统的外部验证。
J Vasc Interv Radiol. 2022 Dec;33(12):1588-1593. doi: 10.1016/j.jvir.2022.08.021. Epub 2022 Aug 20.
2
CT-Guided Microwave Ablation of 45 Renal Tumors: Analysis of Procedure Complexity Utilizing a Percutaneous Renal Ablation Complexity Scoring System.CT引导下45例肾肿瘤的微波消融:利用经皮肾消融复杂性评分系统分析手术复杂性
J Vasc Interv Radiol. 2017 Feb;28(2):222-229. doi: 10.1016/j.jvir.2016.10.013. Epub 2016 Dec 14.
3
Limited ability of the renal ablation-specific (MC)2 risk scoring system to predict major adverse events from percutaneous renal microwave ablation.经皮肾微波消融术所致主要不良事件中,肾消融特异性(MC)2 风险评分系统预测能力有限。
Clin Imaging. 2023 Aug;100:30-35. doi: 10.1016/j.clinimag.2023.05.001. Epub 2023 May 7.
4
Thermal Ablation of T1c Renal Cell Carcinoma: A Comparative Assessment of Technical Performance, Procedural Outcome, and Safety of Microwave Ablation, Radiofrequency Ablation, and Cryoablation.T1c期肾细胞癌的热消融:微波消融、射频消融和冷冻消融的技术性能、手术结果及安全性的比较评估
J Vasc Interv Radiol. 2018 Jul;29(7):943-951. doi: 10.1016/j.jvir.2017.12.020. Epub 2018 Apr 6.
5
Percutaneous Microwave Ablation Versus Cryoablation in the Treatment of T1a Renal Tumors.经皮微波消融与冷冻消融治疗 T1a 期肾肿瘤的比较。
Cardiovasc Intervent Radiol. 2020 Jan;43(1):76-83. doi: 10.1007/s00270-019-02313-7. Epub 2019 Aug 26.
6
Utility of the RENAL Nephrometry Scoring System in Predicting Adverse Events and Outcomes of Percutaneous Microwave Ablation of Renal Tumors.RENAL 评分系统在预测经皮微波消融治疗肾肿瘤不良事件和结局中的应用。
J Vasc Interv Radiol. 2022 Jun;33(6):695-701. doi: 10.1016/j.jvir.2022.03.011. Epub 2022 Mar 17.
7
Comparison of Safety and Efficacy of Percutaneous Microwave Ablation of Central Versus Peripheral Renal Cell Carcinoma.中央与外周肾细胞癌经皮微波消融安全性与疗效的比较。
Cardiovasc Intervent Radiol. 2021 Feb;44(2):281-288. doi: 10.1007/s00270-020-02674-4. Epub 2020 Oct 19.
8
Contrast-enhanced CT immediately following percutaneous microwave ablation of cT1a renal cell carcinoma: Optimizing cancer outcomes.经皮微波消融治疗 cT1a 期肾癌后立即行增强 CT 检查:优化癌症治疗效果。
Abdom Radiol (NY). 2022 Aug;47(8):2674-2680. doi: 10.1007/s00261-022-03481-w. Epub 2022 Mar 12.
9
External Validation of the Renal Ablation-Specific (MC)2 Risk Scoring System in Predicting Complications from Percutaneous Renal Cryoablation.经皮肾冷冻消融术后并发症预测的肾消融特异性(MC)2 风险评分系统的外部验证。
Cardiovasc Intervent Radiol. 2021 Nov;44(11):1763-1768. doi: 10.1007/s00270-021-02929-8. Epub 2021 Jul 29.
10
A multicenter 10-year oncologic outcome of ultrasound-guided percutaneous microwave ablation of clinical T1 renal cell carcinoma: will it stand the test of time?超声引导经皮微波消融治疗临床 T1 期肾癌的 10 年多中心肿瘤学结果:它能经受时间的考验吗?
Eur Radiol. 2022 Jan;32(1):89-100. doi: 10.1007/s00330-021-07900-2. Epub 2021 Jun 30.

引用本文的文献

1
Percutaneous Image-Guided Ablation of Renal Cancer: Traditional and Emerging Indications, Energy Sources, Techniques, and Future Developments.经皮影像引导下的肾癌消融:传统与新出现的适应证、能量来源、技术及未来发展
Medicina (Kaunas). 2025 Feb 28;61(3):438. doi: 10.3390/medicina61030438.
2
External validation of the ability of the mRENAL nephrometry score to identify patients at risk for major adverse events or local tumor recurrence after percutaneous renal cryoablation.mRENAL肾计量评分在经皮肾冷冻消融术后识别有发生重大不良事件或局部肿瘤复发风险患者能力的外部验证。
Abdom Radiol (NY). 2025 Jan;50(1):409-415. doi: 10.1007/s00261-024-04498-z. Epub 2024 Aug 16.
3
Percutaneous Ablation of T1b Renal Cell Carcinoma: An Overview.
经皮消融治疗 T1b 期肾细胞癌:概述。
Curr Oncol Rep. 2024 Jul;26(7):754-761. doi: 10.1007/s11912-024-01531-8. Epub 2024 May 20.